You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study
|
|---|---|
| Published in |
Investigational New Drugs, February 2010
|
| DOI | 10.1007/s10637-010-9396-4 |
| Pubmed ID | |
| Authors |
Cheryl Ho, Randeep Sangha, Laurel Beckett, Michael Tanaka, Derick H. Lau, Daniel B. Eisen, Rachel A. Burich, Paul Luciw, Imran Khan, Philip C. Mack, David R. Gandara, Angela M. Davies |
| Abstract |
Cetuximab is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR). The recommended dosage is an initial load of 400 mg/m² intravenously (IV) followed by a weekly maintenance dose of 250 mg/m². It has been reported retrospectively that cetuximab efficacy was correlated with dose-related severity of skin rash. This study was prospectively designed to examine the safety and feasibility of escalating weekly doses of cetuximab, testing the hypothesis of the relationship of dose-dependent skin toxicity and efficacy. Methods Four dose levels were tested: Cetuximab 400 mg/m² IV loading dose and 250, 300, 350, 400 mg/m² weekly IV maintenance. There was no intra-patient dose escalation. Standard dose limiting toxicity criteria were used. Rash was evaluated using two additional validated dermatology methods: global acne grading scale (GAGS) and acne lesion counting (ALC). Tumor specimens and blood samples were obtained for correlative analyses. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 49 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 18% |
| Other | 7 | 14% |
| Student > Bachelor | 6 | 12% |
| Student > Ph. D. Student | 5 | 10% |
| Professor > Associate Professor | 5 | 10% |
| Other | 12 | 24% |
| Unknown | 7 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 45% |
| Agricultural and Biological Sciences | 6 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Immunology and Microbiology | 2 | 4% |
| Other | 6 | 12% |
| Unknown | 9 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 August 2023.
All research outputs
#7,582,103
of 24,384,776 outputs
Outputs from Investigational New Drugs
#330
of 1,235 outputs
Outputs of similar age
#49,191
of 174,442 outputs
Outputs of similar age from Investigational New Drugs
#4
of 13 outputs
Altmetric has tracked 24,384,776 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 1,235 research outputs from this source. They receive a mean Attention Score of 4.9. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 174,442 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.